• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
VSL
Click for more information
3.85% $8.63

Vulcan Steel Limited Ordinary Shares

watchlist Created with Sketch. Add to my watchlist
Steel Steel

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
VSL
Ann: 2024 Notice of Annual Meeting of shareholders 		30/09/24 0 60
30/09/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  60 
VSL
Ann: Change of Director's Interest Notice - Adrian Casey 		30/09/24 0 31
30/09/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  31 
VSL
Ann: Change of Director's Interest Notice - Rhys Jones 		30/09/24 0 35
30/09/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  35 
VSL
Ann: Lodgement of ASX Appendix 3G and filing of ASX Appendix 2A 		30/09/24 0 41
30/09/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  41 
VSL
Ann: Notice under section 708A(5)(e) of Corporations Act 2001 		30/09/24 0 39
30/09/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  39 
VSL
Ann: ASX Appendix 2A - Application for quotation of securities 		30/09/24 0 43
30/09/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  43 
VSL
Ann: ASX Appendix 3G - Notification of issue of unquoted PSRs 		30/09/24 0 52
30/09/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  52 
VSL
Ann: FY24 - Amended ASX Appendix 3A.1 Dividend for FY24 		27/09/24 0 44
27/09/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  44 

See All Discussions arrow Created with Sketch.

Featured News

NEWS Waroona Project financing strategy aims for non-dilutive funding solutions - discover how this approach will support its Stage One development
right-arrow Created with Sketch.
LU7 Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
right-arrow Created with Sketch.
NEWS Significant increase in revenue from faster NDIS approvals and launch of new leasing programs
right-arrow Created with Sketch.
NEWS Step out drilling confirms high-grade cobalt & associated copper at Bald Hill
right-arrow Created with Sketch.
NEWS High-grade gold discovery at Didievi Project: First drill results reveal impressive 33m intercept at 2.4g/t
right-arrow Created with Sketch.
NEWS Positive diamond results allow for scoping study update
right-arrow Created with Sketch.
(20min delay)
Last
$8.63 		Change
0.320(3.85%) 		Mkt cap ! n/a
Open High Low Value Volume
$8.31 $8.63 $8.31 $49.93K 5.839K

Buyers (Bids)

No. Vol. Price($)
0 1018 $8.10
 

Sellers (Offers)

Price($) Vol. No.
$8.90 52 0
Last trade - 13.00pm 07/10/2024 (20 minute delay) ?
VSL (NZSX) Chart

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Arika Resources Ltd has received commitments from investors in support of a Placement worth $3.2 million to support gold exploration in WA
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03 Nyrada Inc has completed an in-vivo micronucleus on the effects of its NYR-BI03 drug on rats, suggesting it causes no genetic damage
Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.
Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome Neuren has confirmed it's received "positive" FDA responses for its Phase III trial to treat children with Phelan-McDermid syndrome.

Featured News

NEWS Waroona Project financing strategy aims for non-dilutive funding solutions - discover how this approach will support its Stage One development
right-arrow Created with Sketch.
NEWS See what company has secured $98M, 8-year contract renewal with Mercy Health
right-arrow Created with Sketch.
NEWS Antler Copper Project hits major permitting milestone – air quality permit advances to final review
right-arrow Created with Sketch.
NEWS Gold mineralisation discovered along major shear zone at Challa Gold Project, confirming two new intersections in latest aircore drilling
right-arrow Created with Sketch.
NEWS Significant shallow gold intersections at Tambourah King reveal potential extensions to the lode gold system, with promising RC drill results and more assays pending
right-arrow Created with Sketch.
NEWS Significant increase in revenue from faster NDIS approvals and launch of new leasing programs
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.